Angiotensin IV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
The ninth generation BJ Familia was introduced on 9 June 1998 and released on 29 September 1998 as a 1999 model. Body styles included a four-door saloon and a five-door S-Wagon (sold as the Protegé5 in the United States and Canada, 323F in Europe, and as the Astina NU in some Asian countries). In Japan there was also a traditional five-door light van (station wagon for commercial use) sold under the Familia nameplate, but this car was simply a rebadged Nissan. A 4EC automatic transmission and two five-speed manual transmissions were available. All-wheel drive is optional. The Japanese Mazda Familia had all-wheel drive as an option. In North America, the ES's engine was still 1.8 liters, but for the eighth generation it was a smaller version of the 626's engine (the FP) rather than the sportier engine shared with the Miata which had been used previously. The rear disc brakes of the ES were downgraded to drums. Mazda 323s were used as police cars by some police departments such as the Singapore Police Force as Fast Response Cars (FRCs) until they were retired in 2016. The Familia Van and Familia Business Wagon were introduced for 2000, and continued to be supplied by Nissan under an OEM deal, based on the Nissan AD.
=== Design === Designing DNA-binding proteins that have a specified DNA-binding site has been an important goal for biotechnology. Zinc finger proteins have been designed to bind to specific DNA sequences and this is the basis of zinc finger nucleases. Recently transcription activator-like effector nucleases (TALENs) have been created which are based on natural proteins secreted by Xanthomonas bacteria via their type III secretion system when they infect various plant species.
DMT is inactive when ingested orally due to metabolism by monoamine oxidase (MAO), and DMT-containing drinks such as ayahuasca have been found to contain monoamine oxidase inhibitors (MAOIs), in particular, harmine and harmaline. Life-threatening lethalities such as serotonin syndrome (SS) may occur when MAOIs are combined with certain serotonergic medications such as selective serotonin reuptake inhibitor (SSRI) antidepressants. Serotonin syndrome has also been reported with tricyclic antidepressants (TCAs), certain opioids, certain analgesics, and antimigraine drugs; it is advised to exercise caution when an individual has used dextromethorphan (DXM), MDMA, ginseng, or St. John's wort recently. Chronic use of SSRIs, TCAs, and MAOIs diminish subjective effects of psychedelics due to presumed serotonin 5-HT2A receptors downregulation and/or desensitization secondary to elevated serotonin levels. However, a clinical study of people with depression found that SSRIs did not diminish the effects of DMT and instead resulted in greater mystical experience, emotional breakthrough, and ego dissolution scores with DMT than in people with depression not on antidepressants. This was in contrast to previous research finding that SSRIs diminished the effects of serotonergic psychedelics. The interaction between psychedelics and antipsychotics and anticonvulsants are not well documented; however, reports reveal that co-use of psychedelics with mood stabilizers such as lithium may provoke seizure and dissociative effects in individuals with bipolar disorder.
Sources: en.wikipedia.org
Scurvy is a disease resulting from a deficiency of vitamin C. Without this vitamin, collagen made by the body is too unstable to perform its function and several other enzymes in the body do not operate correctly. Early symptoms are malaise and lethargy, progressing to shortness of breath, bone pain and susceptibility to bruising. As the disease progressed, it is characterized by spots on and bleeding under the skin and bleeding gums. The skin lesions are most abundant on the thighs and legs. A person with the ailment looks pale, feels depressed, and is partially immobilized. In advanced scurvy there is fever, old wounds may become open and suppurating, loss of teeth, convulsions and, eventually, death. Until quite late in the disease the damage is reversible, as healthy collagen replaces the defective collagen with vitamin C repletion. Notable human dietary studies of experimentally induced scurvy were conducted on conscientious objectors during World War II in Britain and on Iowa state prisoners in the late 1960s to the 1980s. Men in the prison study developed the first signs of scurvy about four weeks after starting the vitamin C-free diet, whereas in the earlier British study, six to eight months were required, possibly due to the pre-loading of this group with a 70 mg/day supplement for six weeks before the scorbutic diet was fed. Men in both studies had blood levels of ascorbic acid too low to be accurately measured by the time they developed signs of scurvy.
In 2012, a team of researchers at the British chemical and biological defence laboratories at Porton Down found carfentanil and remifentanil in clothing from two British survivors of the 2002 Moscow theater hostage crisis and in the urine from a third survivor. The team concluded that the Russian military had used an aerosol mist of carfentanil and remifentanil to subdue Chechen hostage takers. Researchers had previously surmised from the available evidence that the Moscow emergency services had not been informed of the use of the agent, despite being instructed to bring opioid antagonists to the scene. Unaware that hundreds of patients had been exposed to high doses of strong opioids, the emergency workers failed to bring sufficient quantities of naloxone and naltrexone to counteract the effects of carfentanil and remifentanil. One hundred and twenty-five people exposed to the aerosol are confirmed to have died from respiratory failure during the incident.
=== Legal status === In July 2017, the US Food and Drug Administration (FDA) approved guselkumab for the treatment of plaque psoriasis. In November 2017, Health Canada approved guselkumab for the treatment of plaque psoriasis. In September 2020, the approval was expanded to include the treatment of adults with psoriatic arthritis. In April 2018, guselkumab was approved in Japan for the treatment of psoriatic arthritis. In July 2020, the FDA approved guselkumab as the first IL-23 inhibitor to treat active psoriatic arthritis (PsA). In September 2024, the FDA approved guselkumab for the treatment of moderately to severely active ulcerative colitis in adults. In May 2025, the UK Medicines and Healthcare products Regulatory Agency approved guselkumab for Crohn's disease and ulcerative colitis.
Sources: en.wikipedia.org
=== In fiction === Jonathan Evison's novel, The Revised Fundamentals of Caregiving, published in 2012, depicted a young man affected by the disease. In 2016, Netflix released The Fundamentals of Caring, a film based on the novel.
1993/1359) Fresh Meat and Poultry Meat (Hygiene, Inspection and Examinations for Residues) (Charges) (Amendment) Regulations 1993 (S.I. 1993/1360) Pneumoconiosis, Byssinosis and Miscellaneous Diseases Benefit (Amendment) Scheme 1993 (S.I. 1993/1363) Combined Probation Areas (Devon) Order 1993 (S.I. 1993/1364) Barnet, Camden and Westminster (London Borough Boundaries) Order 1993 (S.I. 1993/1365) Crop Residues (Burning) Regulations 1993 (S.I. 1993/1366) Local Government Superannuation (Local Commissioners) Regulations 1993 (S.I. 1993/1367) National Health Service (Fund-Holding Practices) (Scotland) Amendment Regulations 1993 (S.I. 1993/1369) Lancashire County Council (Proposed Connecting Roads to M6 Motorway at Haighton) Special Roads Scheme 1992 Confirmation Instrument 1993 (S.I. 1993/1370) A17 Trunk Road (Leadenham Bypass) Order 1993 (S.I. 1993/1371) A17 Trunk Road (Leadenham Bypass) (Detrunking) Order 1993 (S.I. 1993/1372) King's Lynn—Newark Trunk Road (Leadenham By-pass and Slip Roads) Order 1973 (Revocation) Order 1993 (S.I. 1993/1373) Registered Restrictive Trading Agreements (Inspection, Copy and Certification) (Fees) Regulations 1993 (S.I. 1993/1376) Greater London and Surrey (County and London Borough Boundaries) (No.4) Order 1993 (S.I. 1993/1391)
The New York State Agricultural Experiment Station recipe for the concentrate suggests starting with 80 lb of sulfur, 36 lb of quicklime, and 50 gal of water, equivalent to 19.172 kg of sulfur and 8.627 kg of calcium oxide per 100 liters of water. About 2.2:1 is the ratio (by weight) for compounding sulfur and quicklime; this ratio yields the highest proportion of calcium pentasulfide. If calcium hydroxide (builders' or hydrated lime) is used, an increase of one-third or more (to 115 g/L or more) may be used with the 192 g/L of sulfur. If the quicklime is 85%, 90%, or 95% pure, 101 g/L, 96 g/L, or 91 g/L is used, respectively; if impure hydrated lime is used, its quantity is increased to compensate, though in practice lime with a purity lower than 90% is rarely used. The mixture is then boiled for one hour while being stirred, and small amounts of water are added for evaporation.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.